Vivos Therapeutics (VVOS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -11.74% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.60% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 89.28% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -30.10% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Vivos Therapeutics | 7.39 Mn | 5.16 Mn | 3.06 Mn | -98.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.81% |
| Dec 31, 2025 | -141.04% |
| Sep 30, 2025 | -106.42% |
| Jun 30, 2025 | -159.74% |
| Mar 31, 2025 | -2.68% |
| Dec 31, 2024 | -130.80% |
| Sep 30, 2024 | -24.99% |
| Jun 30, 2024 | 65.09% |
| Mar 31, 2024 | -120.96% |
| Dec 31, 2023 | 253.83% |
| Sep 30, 2023 | 61.48% |
| Jun 30, 2023 | 20.94% |
| Mar 31, 2023 | 68.05% |
| Dec 31, 2022 | 17.64% |
| Sep 30, 2022 | 0.35% |
| Jun 30, 2022 | -72.94% |
| Mar 31, 2022 | -56.84% |
| Dec 31, 2021 | 35.32% |
| Sep 30, 2021 | -164.30% |
| Jun 30, 2021 | -143.02% |